Physiological modeling is opening up new opportunities to decipher the complexity, variability, and uncertainty within the pathophysiology of disease to provide improved insight, understanding, and decision-making for risk management and success. The elaborate and increasing complexity of remaining disease targets, the business transition from “me too” drug development, and the emergence of precision medicine all call for advanced modeling solutions.
As a result of the applicability, investment, and value of physiological modeling progressively increasing through the R&D drug development process, there is a natural journey of investment that scales with the therapeutic lifecycle. The correlation of the size of models along with the creation of virtual populations to support critical decisions in the R&D continuum means that companies can incrementally invest to support target to approval decisions.
With pharmaceutical company therapeutic focus spanning over decades, physiological simulation investments have the opportunity to be used, advanced, and reused time and time again as therapeutic groups investigate new targets, new therapies, and in-licensing opportunities.
The continued relevance and applicability of the models warrant a strategic investment in the drug industry toward creating complete disease and population models of the pathophysiology for each therapeutic area.